{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:54:37Z","timestamp":1773154477519,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,3,11]],"date-time":"2009-03-11T00:00:00Z","timestamp":1236729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Kidney disease remains a prevalent problem in HIV care. The contribution of highly active antiretroviral therapy (HAART), HIV disease factors and traditional factors needs further evaluation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cross\u2010sectional study of all patients seen at an HIV outpatient clinic during 2005 was performed. All data were collected from medical record review. Multivariate regression modelling was used to identify independent predictors of lower glomerular filtration rate (eGFR) and chronic renal failure (CRF) from factors significant in univariate analysis. eGFR was calculated using the simplified modification of diet in renal disease equation. Results were compared with those for persons from the National Health and Nutrition Examination Survey (NHANES) matched for age, race and gender.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 845 HIV\u2010infected persons, 64% were men and 34% were Caucasian, and the mean age was 39.8 years. Thirty per cent of the patients had proteinuria and 43% had eGFR&lt;90\u2003mL\/min\/1.73\u2003m<jats:sup>2<\/jats:sup>. Persons on HAART (63%) had a lower mean eGFR than those not on HAART (92.0 <jats:italic>vs<\/jats:italic>. 101.6). In multivariate analyses, significant predictors of eGFR decline were diagnoses of hypertension, hyperlipidaemia, proteinuria, use of tenofovir or stavudine, and lower viral load. Compared with those in NHANES, HIV\u2010infected persons had a lower mean eGFR (94.9 <jats:italic>vs<\/jats:italic>. 104.2) and a higher prevalence of CRF (8%<jats:italic>vs<\/jats:italic>. 2%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this cohort, the prevalence of CRF is low, but remains higher than that of the general population. Clinicians should routinely screen for early asymptomatic kidney disease to address risk factors that can be treated.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2009.00693.x","type":"journal-article","created":{"date-parts":[[2009,3,11]],"date-time":"2009-03-11T06:04:47Z","timestamp":1236751487000},"page":"343-350","source":"Crossref","is-referenced-by-count":64,"title":["Factors associated with renal dysfunction within an urban HIV\u2010infected cohort in the era of highly active antiretroviral therapy"],"prefix":"10.1111","volume":"10","author":[{"given":"ET","family":"Overton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Nurutdinova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Seyfried","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KE","family":"Mondy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,6,10]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)24037-2"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/503566"},{"key":"e_1_2_6_4_2","first-page":"1559","article-title":"Guidelines for the management of chronic kidney disease in HIV\u2010infected patients","volume":"40","author":"Gupta SK","year":"2005","journal-title":"recommendations of the HIV Medicine Association of the Infectious Diseases Society of America"},{"key":"e_1_2_6_5_2","first-page":"1331","article-title":"Fanconi syndrome and renal failure induced by tenofovir","volume":"40","author":"Verhelst D","year":"2002","journal-title":"a first case report"},{"key":"e_1_2_6_6_2","first-page":"269","article-title":"Renal tubular dysfunction associated with tenofovir therapy","volume":"35","author":"Peyri\u00e8re H","year":"2004","journal-title":"report of 7 cases"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/428840"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200501030-00012"},{"key":"e_1_2_6_9_2","first-page":"1489","article-title":"Renal dysfunction with tenofovir disoproxil fumarate\u2010containing highly active antiretroviral therapy regimens is not observed more frequently","volume":"37","author":"Jones R","year":"2004","journal-title":"a cohort and case-control study"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005040340"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3280f774ee"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062360"},{"key":"e_1_2_6_13_2","unstructured":"The NHANES 2003\u20132004 datafiles. Available at:http:\/\/www.cdc.gov\/nchs\/about\/major\/nhanes\/nhanes2003\u20102004\/demo03_04.htm. Accessed 14 February 2007."},{"key":"e_1_2_6_14_2","first-page":"S1","article-title":"National Kidney Foundation. K\/DOQI clinical practice guidelines for chronic kidney disease","volume":"39","year":"2002","journal-title":"evaluation, classification, and stratification"},{"key":"e_1_2_6_15_2","first-page":"1377","article-title":"Hypertension among HIV patients","volume":"21","author":"Gazzaruso C","year":"2003","journal-title":"prevalence and relationships to insulin resistance and metabolic syndrome"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.58.072905.180040"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3281fc9320"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00251-06"},{"key":"e_1_2_6_19_2","first-page":"743","article-title":"Long\u2010term renal safety of tenofovir disoproxil fumarate in antiretroviral\u2010na\u00efve HIV\u20101\u2010infected patients","volume":"20","author":"Izzedine H","year":"2005","journal-title":"data from a double-blind randomized active-controlled multicentre study"},{"key":"e_1_2_6_20_2","first-page":"191","article-title":"Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral\u2010na\u00efve patients","volume":"292","author":"Gallant JE","year":"2004","journal-title":"a 3-year randomized trial"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/524061"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100269"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.9.998"},{"key":"e_1_2_6_24_2","first-page":"293","article-title":"Plasma lipids and risk of developing renal dysfunction","volume":"58","author":"Muntner P","year":"2000","journal-title":"the Atherosclerosis Risk in Communities Study"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005121320"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00941.x"},{"key":"e_1_2_6_27_2","first-page":"365","article-title":"Lipoprotein modification","volume":"5","author":"Chait A","year":"1994","journal-title":"cellular mechanisms"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000075925"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra054415"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2009.00693.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2009.00693.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:57:52Z","timestamp":1696867072000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2009.00693.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,10]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1111\/j.1468-1293.2009.00693.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00693.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,10]]}}}